<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460588</url>
  </required_header>
  <id_info>
    <org_study_id>P 140908</org_study_id>
    <secondary_id>2015-000492-27</secondary_id>
    <nct_id>NCT02460588</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>EXAFIP</acronym>
  <official_title>Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major event of IPF with an
      annual incidence between 5 and 10% and is responsible for the death of one third of IPF
      patients. When AE-IPF occurs, it is associated with poor survival with an overall mortality
      at 3 months upper of 50%. To date, no treatment has been proved to be effective in AE-IPF but
      the efficacy of cyclophosphamide (CYC) on survival has been suggested, mainly by
      retrospective series and needs to be confirmed. This confirmation is mandatory to improve
      prognosis of AE-IPF but also to avoid unsuspected deleterious effect as it as been shown with
      immunosuppressor in stable IPF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major event of IPF with an
      annual incidence between 5 and 10% and is responsible for the death of one third of IPF
      patients. When AE-IPF occurs, it is associated with poor survival with an overall mortality
      at 3 months upper of 50%. To date, no treatment has been proved to be effective in AE-IPF but
      the efficacy of CYC on survival has been suggested, mainly by retrospective series and needs
      to be confirmed. This confirmation is mandatory to improve prognosis of AE-IPF but also to
      avoid unsuspected deleterious effect as it as been shown with immunosuppressor in stable IPF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Early&quot; survival</measure>
    <time_frame>3 months</time_frame>
    <description>All cause of mortality at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months and 12 montns</time_frame>
    <description>Overall Survival at M6 and M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory disease-specific mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Respiratory disease-specific mortality at M3 and M6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Morbidity</measure>
    <time_frame>6 months</time_frame>
    <description>\Worsening dyspnea (0-100-mm visual analogue (VAS) scale anchored with 0 ''no breathlessness'' and 10 or 100 ''worst imaginable breathlessness&quot;. Worsening is defined an absolute decrease of 10 mm)
Or Increase need of supplemental oxygen of more than 3l/min to obtained a SaO2 &gt; 90% or decrease of PaO2 of more than 10 mmHg with the same rate of flow supplemental oxygen
Or Decrease FVC of more than 10% of predicted value
Or Decrease diffuse capacity for carbon monoxide (DLCO) of more than 15% prednisolone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest HRCT features (HRCT images will be scored at 5 levels)</measure>
    <time_frame>6 months</time_frame>
    <description>Chest HRCT features at M3 and M6 compared to inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis factors of AE-IPF</measure>
    <time_frame>3 months</time_frame>
    <description>PFTs results before AE-IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to visit after clinical worsening</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory evaluation (LDH, CRP) at AE diagnosis (composite)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis factors of AE-IPF</measure>
    <time_frame>3 months</time_frame>
    <description>PaO2 at AE diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis factors of AE-IPF</measure>
    <time_frame>3 months</time_frame>
    <description>Chest HRCT features at AE diagnosis (HRCT images will be scored at 5 levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to dispense treatment of AE-IPF</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic cystitis (occurence of hematuria on urine dipstick and pelvic pain and/or dysuria should lead to cystoscopy)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infectious disease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes mellitus (capillary blood glucose monitoring and fasting plasma glucose &gt; 1.26 g/l)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension (Blood pressure &gt; 160/100 mmHg)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluation (blood count, serum creatinin measurement composite) according to Common Terminology Criteria for Adverse Event (CTCAE).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Corticosteroid with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
All patients will receive non experimental medication with high dose of corticosteroid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid associated with Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
All patients will receive non experimental medication with high dose of corticosteroid.
Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2</description>
    <arm_group_label>Corticosteroid associated with Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.</description>
    <arm_group_label>Corticosteroid with placebo</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid (prednisolone)</intervention_name>
    <description>All patients will receive non experimental medication with high dose of corticosteroid.</description>
    <arm_group_label>Corticosteroid with placebo</arm_group_label>
    <arm_group_label>Corticosteroid associated with Cyclophosphamide</arm_group_label>
    <other_name>Both groups</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  ≥18 years of age

          -  Definite or probable IPF diagnosis defined on 2011 international recommendations

          -  Definite or suspicion of AE defined by IPFnet criteria after exclusion of alternative
             diagnosis of acute worsening.

          -  Efficient contraceptive method within 1 month for women and 3 months for men after the
             last dose of treatment

          -  Affiliation to the social security

          -  Able to understand and sign a written informed consent form

        Exclusion Criteria:

          -  Identified etiology for acute worsening (i.e. infectious disease)

          -  Known hypersensitivity or contra-indication to CYC or to any component of the study
             treatment

          -  Patient on mechanical ventilation

          -  Active bacterial, viral, fungal or parasitic infection

          -  Active cancer

          -  Patient on a lung transplantation waiting list

          -  Treatment with CYC in the last 12 months

          -  Patient participating to another clinical trial

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc NACCACHE, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marc NACCACHE, PH</last_name>
    <phone>33 (0)1 56 01 61 96</phone>
    <email>jean-marc.naccache@tnn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilario NUNES, PU-PH</last_name>
    <phone>33(0)3 48 95 51 21</phone>
    <email>hilario.nunes@avc.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc NACCACHE</last_name>
      <phone>33 (0)1 56 01 61 96</phone>
      <email>jean-marc.naccache@tnn.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.</citation>
    <PMID>22607134</PMID>
  </reference>
  <reference>
    <citation>Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43. Epub 2007 Jun 21. Review.</citation>
    <PMID>17585107</PMID>
  </reference>
  <reference>
    <citation>Oishi K, Mimura-Kimura Y, Miyasho T, Aoe K, Ogata Y, Katayama H, Murata Y, Ueoka H, Matsumoto T, Mimura Y. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013 Jan;61(1):84-9. doi: 10.1016/j.cyto.2012.08.032. Epub 2012 Sep 26.</citation>
    <PMID>23021430</PMID>
  </reference>
  <reference>
    <citation>Morawiec E, Tillie-Leblond I, Pansini V, Salleron J, Remy-Jardin M, Wallaert B. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J. 2011 Dec;38(6):1487-9. doi: 10.1183/09031936.00127311.</citation>
    <PMID>22130770</PMID>
  </reference>
  <reference>
    <citation>Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, Denis D, Cohen Y, Vincent F, Valeyre D, Naccache JM. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28-35. doi: 10.1159/000329891. Epub 2011 Aug 23.</citation>
    <PMID>21860222</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008 Jun;19(4):227-35. doi: 10.1016/j.ejim.2007.04.024. Epub 2008 Jan 16. Review.</citation>
    <PMID>18471669</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.</citation>
    <PMID>21471066</PMID>
  </reference>
  <reference>
    <citation>Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Cordier JF, Aguilaniu B, Bouquillon B, Carré P, Danel C, Faivre JB, Ferreti G, Just N, Kouzan S, Lebargy F, Marchand Adam S, Philippe B, Prévot G, Stach B, Thivolet-Béjui F; French National Reference and Competence Centers for Rare Diseases; Societe de Pneumologies de Langue Francaise. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française]. Rev Mal Respir. 2013 Dec;30(10):879-902. doi: 10.1016/j.rmr.2013.09.007. Epub 2013 Oct 25. French. Erratum in: Rev Mal Respir. 2014 Feb;31(2):194-5.</citation>
    <PMID>24314711</PMID>
  </reference>
  <reference>
    <citation>Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012 Dec 1;21(126):355-61. doi: 10.1183/09059180.00002512. Review.</citation>
    <PMID>23204124</PMID>
  </reference>
  <reference>
    <citation>Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen JA, Wells AU, Verleden GM. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013 May;41(5):1207-18. doi: 10.1183/09031936.00073012. Epub 2012 Oct 25. Review.</citation>
    <PMID>23100500</PMID>
  </reference>
  <reference>
    <citation>Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):963-7.</citation>
    <PMID>15968010</PMID>
  </reference>
  <reference>
    <citation>Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013 Jul 13;14:73. doi: 10.1186/1465-9921-14-73.</citation>
    <PMID>23848435</PMID>
  </reference>
  <reference>
    <citation>Churg A, Müller NL, Silva CI, Wright JL. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol. 2007 Feb;31(2):277-84.</citation>
    <PMID>17255773</PMID>
  </reference>
  <reference>
    <citation>Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, Roussos C. Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread. Crit Care. 2010;14(6):246. doi: 10.1186/cc9241. Epub 2010 Dec 22. Review.</citation>
    <PMID>21235829</PMID>
  </reference>
  <reference>
    <citation>Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011 Feb;37(2):356-63. doi: 10.1183/09031936.00159709. Epub 2010 Jul 1.</citation>
    <PMID>20595144</PMID>
  </reference>
  <reference>
    <citation>Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Aug 15;178(4):372-8. doi: 10.1164/rccm.200709-1365OC. Epub 2008 May 1.</citation>
    <PMID>18451320</PMID>
  </reference>
  <reference>
    <citation>Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003 Nov;22(5):821-6.</citation>
    <PMID>14621091</PMID>
  </reference>
  <reference>
    <citation>Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006 Jan;27(1):143-50.</citation>
    <PMID>16387947</PMID>
  </reference>
  <reference>
    <citation>Fujimoto K, Taniguchi H, Johkoh T, Kondoh Y, Ichikado K, Sumikawa H, Ogura T, Kataoka K, Endo T, Kawaguchi A, Müller NL. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol. 2012 Jan;22(1):83-92. doi: 10.1007/s00330-011-2211-6. Epub 2011 Aug 7.</citation>
    <PMID>21822949</PMID>
  </reference>
  <reference>
    <citation>Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, du Bois RM. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006 Oct;100(10):1753-9. Epub 2006 Apr 3.</citation>
    <PMID>16584880</PMID>
  </reference>
  <reference>
    <citation>Rice AJ, Wells AU, Bouros D, du Bois RM, Hansell DM, Polychronopoulos V, Vassilakis D, Kerr JR, Evans TW, Nicholson AG. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. Am J Clin Pathol. 2003 May;119(5):709-14.</citation>
    <PMID>12760290</PMID>
  </reference>
  <reference>
    <citation>Tomioka H, Sakurai T, Hashimoto K, Iwasaki H. Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumoniae infection. Respirology. 2007 Sep;12(5):700-6.</citation>
    <PMID>17875058</PMID>
  </reference>
  <reference>
    <citation>de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19;150(10):670-80.</citation>
    <PMID>19451574</PMID>
  </reference>
  <reference>
    <citation>Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655-66.</citation>
    <PMID>16790698</PMID>
  </reference>
  <reference>
    <citation>Cottin V, Cadranel J, Crestani B, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Valeyre D, Wallaert B, Bouquillon B, Cordier JF. Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med. 2014 Jan;108(1):195-202. doi: 10.1016/j.rmed.2013.11.017. Epub 2013 Dec 3.</citation>
    <PMID>24361163</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

